Drug intelligence / Profile preview

LF-LV-GT-010

Development stage: Preclinical
Lead developer: Shanghai LIFE Medical Science and Technology
Modality: Gene Therapies

Overview

LF-LV-GT-010 is an investigational lentiviral-based gene therapy currently in preclinical development for the treatment of solid tumors. Developed by Shanghai LIFE Medical Science and Technology, the candidate utilizes a lentiviral vector system to deliver therapeutic genetic material to tumor cells. While the specific transgene and molecular target have not been disclosed, the therapy is designed to address the complexities of solid tumor biology through genetic modification. It is part of the company's broader pipeline focusing on lentivirus-based cell and gene therapy products.

Beyond the preview

Go deeper on LF-LV-GT-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LF-LV-GT-010.

Explore the full profile